MORC3 and dermatomyositis: In 2017, Albayda et al1 demonstrated in a cohort of 56 patients with dermatomyositis with anti-NXP2 antibodies that there was a statistically significant increase in the likelihood of subcutaneous edema when compared to patients with NXP2-negative dermatomyositis (36% vs 19%; P = .01).1